Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$3.21 +5.6%	$2.95	$0.40 ▼ $5.48	$71.57M	0.27	185,484 shs	143,490 shs
DTIL Precision BioSciences	$4.96 +4.6%	$4.65	$3.61 ▼ $11.09	$55.87M	1.52	84,524 shs	65,715 shs
FLGC Flora Growth	$21.26 +6.7%	$23.61	$15.15 ▼ $82.29	$11.53M	1.97	17,871 shs	3,587 shs
PDSB PDS Biotechnology	$1.19 +3.5%	$1.27	$0.85 ▼ $4.29	$53.63M	0.95	326,980 shs	240,476 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-1.62%	0.00%	+1.00%	+164.35%	+316.04%
DTIL Precision BioSciences	+1.72%	-0.63%	-2.47%	+3.49%	-51.78%
FLGC Flora Growth	-2.40%	-15.23%	-21.90%	-27.24%	-45.66%
PDSB PDS Biotechnology	-1.71%	-4.17%	0.00%	-27.22%	-66.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.3014 of 5 stars	0.0	3.0	0.0	1.6	0.8	0.0
DTIL Precision BioSciences	4.1627 of 5 stars	3.5	1.0	4.6	3.5	1.7	0.6
FLGC Flora Growth	3.3329 of 5 stars	3.5	5.0	0.0	3.3	0.8	0.6
PDSB PDS Biotechnology	2.2133 of 5 stars	3.5	3.0	0.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
DTIL Precision BioSciences	3.00	Buy	$47.00	847.58% Upside
FLGC Flora Growth	3.00	Buy	$93.00	337.46% Upside
PDSB PDS Biotechnology	3.00	Buy	$10.00	740.34% Upside

Current Analyst Ratings Breakdown

Latest FLGC, ABVC, DTIL, and PDSB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	FLGC Flora Growth	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$30.00
7/1/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/11/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	148.16	N/A	N/A	$0.40 per share	8.03
DTIL Precision BioSciences	$1.26M	46.36	N/A	N/A	$2.89 per share	1.72
FLGC Flora Growth	$59.51M	0.21	N/A	N/A	$6.95 per share	3.06
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.17	N/A	∞	N/A	-963.46%	-46.76%	-23.02%	N/A
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
FLGC Flora Growth	-$15.91M	-$34.38	N/A	N/A	N/A	-24.86%	-261.57%	-48.06%	N/A
PDSB PDS Biotechnology	-$37.61M	-$0.92	N/A	N/A	N/A	N/A	-184.56%	-79.00%	N/A

Latest FLGC, ABVC, DTIL, and PDSB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ABVC ABVC BioPharma	N/A	-$0.13	N/A	-$0.13	N/A	N/A
8/13/2025	Q2 2025	PDSB PDS Biotechnology	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million
8/1/2025	Q2 2025	FLGC Flora Growth	-$0.06	-$0.11	-$0.05	-$0.11	$11.77 million	$14.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.42	0.42
DTIL Precision BioSciences	0.66	5.18	5.18
FLGC Flora Growth	0.50	0.96	0.61
PDSB PDS Biotechnology	0.81	2.92	2.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
DTIL Precision BioSciences	37.99%
FLGC Flora Growth	36.01%
PDSB PDS Biotechnology	26.84%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
DTIL Precision BioSciences	4.50%
FLGC Flora Growth	12.56%
PDSB PDS Biotechnology	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	23.54 million	14.08 million	Not Optionable
DTIL Precision BioSciences	200	11.79 million	11.26 million	No Data
FLGC Flora Growth	280	580,000	506,000	Not Optionable
PDSB PDS Biotechnology	20	46.63 million	42.34 million	Optionable

FLGC, ABVC, DTIL, and PDSB Headlines

Recent News About These Companies

Q3 EPS Forecast for PDS Biotechnology Boosted by Analyst

August 17, 2025 | marketbeat.com

HC Wainwright Issues Positive Estimate for PDSB Earnings

August 17, 2025 | americanbankingnews.com

PDS Biotechnology (NASDAQ:PDSB) Announces Quarterly Earnings Results

August 15, 2025 | marketbeat.com

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

August 14, 2025 | prnewswire.co.ukP

PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call Transcript

August 14, 2025 | insidermonkey.com

PDS Biotechnology Reports Q2 2025 Financial Results

August 14, 2025 | msn.com

PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

PDS Biotechnology reports Q2 EPS (21c), consensus (23c)

August 13, 2025 | msn.com

PDSB Loss Improves as Costs Drop

August 13, 2025 | aol.comA

PDS Biotechnology: Q2 Earnings Snapshot

August 13, 2025 | stamfordadvocate.comS

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

August 13, 2025 | globenewswire.com

Insights into PDS Biotechnology's Upcoming Earnings

August 12, 2025 | benzinga.com

PDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

PDS Biotechnology (NASDAQ:PDSB) Trading 8.7% Higher - What's Next?

July 24, 2025 | marketbeat.com

PDS wasn’t a bad deal, few greedy individuals cannibalised it with self-serving interests – John Jinapor

July 16, 2025 | modernghana.comM

PDS deal was not bad but greedy people decided to cannibalise the process - Jinapor

July 16, 2025 | ghanaweb.comG

Energy Minister blames ‘greedy individuals’ for undermining ‘otherwise good’ PDS deal

July 16, 2025 | myjoyonline.comM

PDS to pay final dividend of ₹1.70, ex-date due tomorrow; last day today to trade shares

July 16, 2025 | moneycontrol.com

The top headlines for PDS Health’s busy 2025 so far

July 12, 2025 | beckersdental.comB

PDS Biotechnology stock rises after trial meets criteria for expansion

July 10, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC, ABVC, DTIL, and PDSB Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$3.21 +0.17 (+5.59%)

Closing price 04:00 PM Eastern

Extended Trading

$3.25 +0.04 (+1.25%)

As of 07:59 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Precision BioSciences NASDAQ:DTIL

$4.96 +0.22 (+4.64%)

Closing price 04:00 PM Eastern

Extended Trading

$4.94 -0.01 (-0.30%)

As of 06:31 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Flora Growth NASDAQ:FLGC

$21.26 +1.34 (+6.72%)

Closing price 03:58 PM Eastern

Extended Trading

$21.89 +0.63 (+2.97%)

As of 06:35 PM Eastern

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

PDS Biotechnology NASDAQ:PDSB

$1.19 +0.04 (+3.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 0.00 (-0.42%)

As of 07:02 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time